Jingxin Pharmaceutical’s Didaxini Gains NMPA Approval as Category 1 Drug
Jingxin Pharmaceutical Co., Ltd (SHE: 002020), a Chinese pharmaceutical company, has announced that it has...
Biocytogen Pharmaceuticals Secures US Patent for Fully Human Antibody Mice Platform RenMab
Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315), a China-based Contract Research Organization (CRO), has announced...
China’s Betta Pharmaceuticals Advances CFT8919 for EGFR-Mutated NSCLC After NMPA Approval
Betta Pharmaceuticals Co., Ltd (SHE: 300558), a Chinese pharmaceutical company, has announced that it has...
Ascletis Pharma’s Denifanstat Advances to Phase III for Severe Acne Vulgaris Treatment
Ascletis Pharma Inc., (HKG: 1672) a China-based biotechnology company, has announced the commencement of a...
Sino Medical Secures Market Approval in Taiwan for NC Rockstar Coronary Catheter
Sino Medical Sciences Technology Inc. (SHA: 688108) has announced that its NC Rockstar non-compliant coronary...
Luye Pharma’s Lurbinectedin for Metastatic SCLC Wins Macau Regulatory Nod
Luye Pharma Group (HKG: 2186), a Chinese pharmaceutical company, has announced that Macau’s medical products...
Yantai Dongcheng Pharmaceutical Gets NMPA Green Light for FAP-Targeting Radiotherapeutic Drug
Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a Chinese pharmaceutical company, has received approval...
Tonghua Dongbao Pharmaceuticals Secures NMPA Approval for Biosimilar Liraglutide
Tonghua Dongbao Pharmaceuticals (SHA: 600867), a Chinese pharmaceutical company, has announced that it has received...
Simcere Pharmaceutical’s SIM0501 Receives FDA Approval for Advanced Solid Tumor Clinical Trial
Simcere Pharmaceutical Group (HKG: 2096) has announced that it has received clinical trial approval from...
WuXi Biologics Shares Plunge 22% on Slower CDMO Industry Growth and Revenue Shortfall
WuXi Biologics (HKG: 2269) experienced a 22% decline in its share price on Monday, December...
Abbisko Therapeutics Strikes Licensing Deal with Merck KGaA for CSF-1R Inhibitor Pimicotinib
Abbisko Therapeutics Co., Ltd (HKG: 2256), a Shanghai-based biotechnology company, has announced a licensing agreement...
Boehringer Ingelheim Partners with Shanghai Handu Pharma to Enhance Oral Medication Delivery
Boehringer Ingelheim (BI), a German pharmaceutical company, has entered into a partnership with Shanghai Handu...
Gedeon Richter Acquires Rights to Mithra’s Contraceptive and Menopause Treatments for Chinese Market
Gedeon Richter Plc, a Hungarian pharmaceutical company, and Belgium’s Mithra (OTCMKTS: MITPF) have entered into...
Aspen Pharmacare Holdings to Boost China Presence with Full Acquisition of Sandoz’s Subsidiary
Aspen Pharmacare Holdings (JSE: APN), a South Africa-based pharmaceutical company, is poised to enhance its...
AstraZeneca Halts Late-Stage Trials for Lokelma in Hyperkalemia Due to Timing and Event Rate Issues
AstraZeneca (AZ; NASDAQ: AZN), a leading UK pharmaceutical company, has announced the termination of two...
Roche Expands Beyond Oncology with USD 2.7 Billion Carmot Therapeutics Acquisition
Swiss pharmaceutical giant Roche (SWX: ROG) has entered into an agreement to acquire U.S. biotech...
Stem-Cell Startup Xellsmart Earns FDA Orphan Drug Designation for ALS Therapy
Xellsmart, a stem-cell startup headquartered in Suzhou, has announced that it has received orphan drug...
Worg Pharmaceuticals Gets FDA Approval for Phase II Graves’ Disease Study
Worg Pharmaceuticals, a Hangzhou-based developer of allergic drugs, has received the green light from the...
Nanchang Baiji Pharmaceutical’s Budesonide Nasal Spray Approved by China’s NMPA
Nanchang Baiji Pharmaceutical Co. Ltd., a Chinese pharmaceutical company, has received approval from the National...
Eli Lilly’s Jaypirca Receives FDA Accelerated Approval for Chronic Lymphocytic Leukemia
The US Food and Drug Administration (FDA) has granted Eli Lilly (NYSE: LLY) an accelerated...